Matches in SemOpenAlex for { <https://semopenalex.org/work/W2913213195> ?p ?o ?g. }
- W2913213195 endingPage "15" @default.
- W2913213195 startingPage "7" @default.
- W2913213195 abstract "Background The current results of endovascular repair of abdominal aortic aneurysms (EVAR) and the wide use of percutaneous closure systems suggest that ambulatory treatment is feasible in selected patients. The objective of this study was to evaluate the rate of eligibility to ambulatory EVAR (EVAR-Ambu) and its potential medicoeconomic impact. Methods Between January 2014 and December 2016, 245 patients were operated of an abdominal aortic aneurysm (AAA) in our center. The 128 patients whose anatomy was unfavorable with EVAR, which were operated in urgency or who were classified as American society of anesthesiologists 4, were excluded from the study. The 117 remaining files were reexamined to evaluate the eligibility for EVAR-Ambu retrospectively. The patients were considered as eligible if they presented all the following criteria: (1) normal surgical risk, (2) logistic feasibility of an ambulatory procedure (home <1 hr away from the hospital, available relatives), and (3) anatomical criteria of percutaneous feasibility according to angio–computed tomography. The surgical risk was evaluated according to the French High Health Authority (HAS) and the Society for Vascular Surgery (SVS) score. The balance between costs and revenue was evaluated for each patient according to the length of stay. Results Among the 117 patients, 43 (37%) and 57 (49%) were eligible for EVAR-Ambu by percutaneous route according to whether the surgical risk was assessed according to the HAS or the SVS criteria. If a conventional surgical approach was considered as compatible with EVAR-Ambu, 12 (10%) and 13 (11%) additional patients were eligible according to whether the surgical risk was assessed according to the HAS or the SVS criteria, respectively. In terms of medicoeconomic evaluation, the cost of the initial intervention depended was mainly on the cost of the stent graft and the operating room services. The cost spent of 1 night conventional hospitalization (CH) after EVAR was 603€ per day versus 490€ in the Day Surgery Unit (DSU). In comparison, the revenue for the institution was identical for DSU and a 1-night CH. According to our estimates, the balance between revenue and expenditures amounted to +122€ per patient for EVAR-Ambu versus +10€ or +119€ per patient hospitalized 1 or 2 nights, respectively. Conclusions EVAR-Ambu is possible in a substantial proportion of patients treated for infrarenal AAA. Its medicoeconomic interest is real for the health system although it appears low at the individual level. The safety of this approach in clinical practice must be confirmed by a prospective study in selected patients. The current results of endovascular repair of abdominal aortic aneurysms (EVAR) and the wide use of percutaneous closure systems suggest that ambulatory treatment is feasible in selected patients. The objective of this study was to evaluate the rate of eligibility to ambulatory EVAR (EVAR-Ambu) and its potential medicoeconomic impact. Between January 2014 and December 2016, 245 patients were operated of an abdominal aortic aneurysm (AAA) in our center. The 128 patients whose anatomy was unfavorable with EVAR, which were operated in urgency or who were classified as American society of anesthesiologists 4, were excluded from the study. The 117 remaining files were reexamined to evaluate the eligibility for EVAR-Ambu retrospectively. The patients were considered as eligible if they presented all the following criteria: (1) normal surgical risk, (2) logistic feasibility of an ambulatory procedure (home <1 hr away from the hospital, available relatives), and (3) anatomical criteria of percutaneous feasibility according to angio–computed tomography. The surgical risk was evaluated according to the French High Health Authority (HAS) and the Society for Vascular Surgery (SVS) score. The balance between costs and revenue was evaluated for each patient according to the length of stay. Among the 117 patients, 43 (37%) and 57 (49%) were eligible for EVAR-Ambu by percutaneous route according to whether the surgical risk was assessed according to the HAS or the SVS criteria. If a conventional surgical approach was considered as compatible with EVAR-Ambu, 12 (10%) and 13 (11%) additional patients were eligible according to whether the surgical risk was assessed according to the HAS or the SVS criteria, respectively. In terms of medicoeconomic evaluation, the cost of the initial intervention depended was mainly on the cost of the stent graft and the operating room services. The cost spent of 1 night conventional hospitalization (CH) after EVAR was 603€ per day versus 490€ in the Day Surgery Unit (DSU). In comparison, the revenue for the institution was identical for DSU and a 1-night CH. According to our estimates, the balance between revenue and expenditures amounted to +122€ per patient for EVAR-Ambu versus +10€ or +119€ per patient hospitalized 1 or 2 nights, respectively. EVAR-Ambu is possible in a substantial proportion of patients treated for infrarenal AAA. Its medicoeconomic interest is real for the health system although it appears low at the individual level. The safety of this approach in clinical practice must be confirmed by a prospective study in selected patients." @default.
- W2913213195 created "2019-02-21" @default.
- W2913213195 creator A5027164655 @default.
- W2913213195 creator A5027638250 @default.
- W2913213195 creator A5035736692 @default.
- W2913213195 creator A5076765829 @default.
- W2913213195 creator A5078188114 @default.
- W2913213195 date "2019-07-01" @default.
- W2913213195 modified "2023-10-10" @default.
- W2913213195 title "Eligibility Rates for Ambulatory EVAR" @default.
- W2913213195 cites W1495226052 @default.
- W2913213195 cites W1970144614 @default.
- W2913213195 cites W1982967737 @default.
- W2913213195 cites W1996222586 @default.
- W2913213195 cites W2004772674 @default.
- W2913213195 cites W2006481445 @default.
- W2913213195 cites W2026892329 @default.
- W2913213195 cites W2050359592 @default.
- W2913213195 cites W2057151616 @default.
- W2913213195 cites W2072824200 @default.
- W2913213195 cites W2082519425 @default.
- W2913213195 cites W2099641905 @default.
- W2913213195 cites W2100850234 @default.
- W2913213195 cites W2118396626 @default.
- W2913213195 cites W2126244687 @default.
- W2913213195 cites W2140579637 @default.
- W2913213195 cites W2148903912 @default.
- W2913213195 cites W2151042489 @default.
- W2913213195 cites W2154986758 @default.
- W2913213195 cites W2167845817 @default.
- W2913213195 cites W2254507851 @default.
- W2913213195 cites W2273883521 @default.
- W2913213195 cites W2317325714 @default.
- W2913213195 cites W2561449060 @default.
- W2913213195 cites W2579139898 @default.
- W2913213195 cites W2604435658 @default.
- W2913213195 cites W2606438708 @default.
- W2913213195 cites W2626415883 @default.
- W2913213195 cites W2753380358 @default.
- W2913213195 cites W2780669507 @default.
- W2913213195 cites W2785989107 @default.
- W2913213195 cites W2792531422 @default.
- W2913213195 cites W2899684260 @default.
- W2913213195 doi "https://doi.org/10.1016/j.avsg.2018.10.047" @default.
- W2913213195 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30735768" @default.
- W2913213195 hasPublicationYear "2019" @default.
- W2913213195 type Work @default.
- W2913213195 sameAs 2913213195 @default.
- W2913213195 citedByCount "4" @default.
- W2913213195 countsByYear W29132131952020 @default.
- W2913213195 countsByYear W29132131952021 @default.
- W2913213195 countsByYear W29132131952022 @default.
- W2913213195 crossrefType "journal-article" @default.
- W2913213195 hasAuthorship W2913213195A5027164655 @default.
- W2913213195 hasAuthorship W2913213195A5027638250 @default.
- W2913213195 hasAuthorship W2913213195A5035736692 @default.
- W2913213195 hasAuthorship W2913213195A5076765829 @default.
- W2913213195 hasAuthorship W2913213195A5078188114 @default.
- W2913213195 hasBestOaLocation W29132131951 @default.
- W2913213195 hasConcept C141071460 @default.
- W2913213195 hasConcept C2776098176 @default.
- W2913213195 hasConcept C2776543907 @default.
- W2913213195 hasConcept C2779993416 @default.
- W2913213195 hasConcept C2780120127 @default.
- W2913213195 hasConcept C2780813298 @default.
- W2913213195 hasConcept C35785553 @default.
- W2913213195 hasConcept C61434518 @default.
- W2913213195 hasConcept C71924100 @default.
- W2913213195 hasConceptScore W2913213195C141071460 @default.
- W2913213195 hasConceptScore W2913213195C2776098176 @default.
- W2913213195 hasConceptScore W2913213195C2776543907 @default.
- W2913213195 hasConceptScore W2913213195C2779993416 @default.
- W2913213195 hasConceptScore W2913213195C2780120127 @default.
- W2913213195 hasConceptScore W2913213195C2780813298 @default.
- W2913213195 hasConceptScore W2913213195C35785553 @default.
- W2913213195 hasConceptScore W2913213195C61434518 @default.
- W2913213195 hasConceptScore W2913213195C71924100 @default.
- W2913213195 hasLocation W29132131951 @default.
- W2913213195 hasLocation W29132131952 @default.
- W2913213195 hasLocation W29132131953 @default.
- W2913213195 hasLocation W29132131954 @default.
- W2913213195 hasLocation W29132131955 @default.
- W2913213195 hasLocation W29132131956 @default.
- W2913213195 hasOpenAccess W2913213195 @default.
- W2913213195 hasPrimaryLocation W29132131951 @default.
- W2913213195 hasRelatedWork W1996097135 @default.
- W2913213195 hasRelatedWork W2053330651 @default.
- W2913213195 hasRelatedWork W2061253854 @default.
- W2913213195 hasRelatedWork W2119172533 @default.
- W2913213195 hasRelatedWork W2330404122 @default.
- W2913213195 hasRelatedWork W2621294089 @default.
- W2913213195 hasRelatedWork W2947783996 @default.
- W2913213195 hasRelatedWork W2951555197 @default.
- W2913213195 hasRelatedWork W3037686638 @default.
- W2913213195 hasRelatedWork W4252135025 @default.
- W2913213195 hasVolume "58" @default.
- W2913213195 isParatext "false" @default.
- W2913213195 isRetracted "false" @default.